Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07278336 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer | PHASE1 | RECRUITING | 207 | — | — | Nov 27, 2025 | Jan 1, 2029 | Jan 20, 2026 | 8 | United States, Israel +1 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment.
Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by the investigator.
| Arm | Type | Description |
|---|---|---|
| Part 1: ABBV-901 Dose Escalation | EXPERIMENTAL | Participants will receive escalating doses of ABBV-901 alone, as part of the approximately 3 year study duration. |
| Part 2: ABBV-901 Optimization/Expansion Dose A | EXPERIMENTAL | Participants will receive ABBV-901 dose A alone, as part of the approximately 3 year study duration. |
| Part 2: ABBV-901 Optimization/Expansion Dose B | EXPERIMENTAL | Participants will receive ABBV-901 dose B alone, as part of the approximately 3 year study duration. |
| Part 2: ABBV-901 Optimization/Expansion Dose C | EXPERIMENTAL | Participants will receive ABBV-901 dose C alone, as part of the approximately 3 year study duration. |
| Part 3: ABBV-901 + Bevacizumab Escalation | EXPERIMENTAL | Participants will receive escalating doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration. |
| Part 4: ABBV-901 + Bevacizumab Expansion | EXPERIMENTAL | Participants will receive the recommended doses for expansion doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration. |
| Name | Type | Description |
|---|---|---|
| ABBV-901 | DRUG | Intravenous (IV) |
| Bevacizumab | DRUG | IV |
Inclusion Criteria: * Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization \[WHO\] criteria). * Participants must be consider...